cwerbBI2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival
1997

c-erbB-2 Oncoprotein and Breast Cancer Survival

Sample size: 148 publication Evidence: moderate

Author Information

Author(s): C Charpin, S Garcia, C Bouvier, F Martini, M-N Lavaut, C Allasia, P Bonnier, L Andrac

Primary Institution: Department of Pathology, EA 875 'Oncogenese des tumeurs solides', Faculté de Médecine, Marseilles, France

Hypothesis

The study investigates the prognostic significance of c-erbB-2 oncoprotein overexpression in breast carcinomas.

Conclusion

c-erbB-2 expression is a significant prognostic indicator for overall and disease-free survival in breast cancer patients.

Supporting Evidence

  • Patients with c-erbB-2 positive surfaces greater than 35% had poorer overall survival.
  • Marked c-erbB-2 expression correlated with shorter disease-free survival in node-positive patients.
  • Immunocytochemical assays were performed under optimal technical conditions.

Takeaway

This study found that higher levels of a protein called c-erbB-2 in breast cancer can mean patients might not live as long or have more problems after treatment.

Methodology

Automated immunocytochemical assays were performed on frozen tissue sections to evaluate c-erbB-2 expression.

Limitations

The study may have limitations due to variations in technical procedures and the lack of standardized evaluation methods.

Participant Demographics

Patients aged 34 to 79 years, with a mean age of 53.2 years.

Statistical Information

P-Value

P = 0.045 for overall survival in N- patients; P = 0.015 for overall survival in N+ patients; P = 0.005 for disease-free survival in N+ patients.

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication